Țară: Israel
Limbă: engleză
Sursă: Ministry of Health
CEFTRIAXONE AS SODIUM
K.S.KIM INTERNATIONAL (SK- PHARMA) LTD., ISRAEL
J01DD04
POWDER FOR SOLUTION FOR INJECTION
CEFTRIAXONE AS SODIUM 1000 MG/VIAL
I.M, I.V
Required
ANFARM HELLAS S.A., GREECE
CEFTRIAXONE
Ceftriaxone S.K. is indicated for the treatment of the following infections in adults and children including term neonates (from birth): - Bacterial Meningitis - Community acquired pneumonia - Hospital acquired pneumonia - Acute otitis media - Intra-abdominal infections - Complicated urinary tract infections (including pyelonephritis) - Infections of bones and joints - Complicated skin and soft tissue infections - Gonorrhoea - Syphilis - Bacterial endocarditisCeftriaxone S.K. may be used: - For treatment of acute exacerbations of chronic obstructive pulmonary disease in adults - For treatment of disseminated Lyme borreliosis (early (stage II) and late (stage III) in adults and children including neonates from 15 days of age. - For pre-operative prophylaxis of surgical site infections - In the management of neutropenic patients with fever that is suspected to be due to a ceftriaxone – susceptible bacterial infection - In the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above
2022-09-30
Page 1 of 24 CEFTRIAXONE S.K. POWDER FOR SOLUTION FOR INJECTION 1. NAME OF THE MEDICINAL PRODUCT Ceftriaxone S.K. 1000 mg Powder for solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial Ceftriaxone S.K. contains 1,193 mg of ceftriaxone sodium, equivalent to 1000 mg of ceftriaxone. Excipient with known effect: Sodium 1000 mg vial contains 3.6 mmol (or 83 mg) of sodium per vial. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for solution for injection. Almost white or yellowish powder. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ceftriaxone S.K. is indicated for the treatment of the following infections in adults and children including term neonates (from birth): − Bacterial Meningitis − Community acquired pneumonia − Hospital acquired pneumonia − Acute otitis media − Intra-abdominal infections − Complicated urinary tract infections (including pyelonephritis) − Infections of bones and joints − Complicated skin and soft tissue infections − Gonorrhoea − Syphilis Page 2 of 24 − Bacterial endocarditis Ceftriaxone S.K. may be used: − For treatment of acute exacerbations of chronic obstructive pulmonary disease in adults. − For treatment of disseminated Lyme borreliosis (early (stage II) and late (stage III) in adults and children including neonates from 15 days of age. − For pre-operative prophylaxis of surgical site infections. − In the management of neutropenic patients with fever that is suspected to be due to a ceftriaxone–susceptible bacterial infection. − In the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Ceftriaxone S.K. should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum (see section 4.4). Consideration should be given to official guidelines on the appropriate use of antibacterial agents. 4.2 POSOLOGY AND METHOD OF ADMINISTRAT Citiți documentul complet